Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cytarabine + idarubicin + mitoxantrone
- Development stage
- Phase 3
- Lead developer
- Grupo Argentino de Tratamiento de la Leucemia Aguda
- Modality
- Small Molecules
- Administration
- Intravenous, Intrathecal
01
Overview
ARM B refers to a specific consolidation chemotherapy regimen evaluated in the GATLA 8-LMA-P'07 (also known as GATLA 8-AML'07) phase III clinical trial for pediatric patients with acute myeloid leukemia (AML). Developed by the Grupo Argentino de Tratamiento de la Leucemia Aguda (GATLA), this "block therapy" approach was designed to replace conventional 6-drug consolidation. The regimen consists of two sequential blocks: Block AI (intermediate-dose cytarabine and idarubicin) and Block haM (high-dose cytarabine and mitoxantrone). Both blocks include intrathecal cytarabine for central nervous system prophylaxis. The regimen aims to optimize dose intensity and reduce residual disease while managing toxicity in children and adolescents with AML.
- Other names
- Blocks Therapy AI and haMGATLA 8-AML'07 Arm BGATLA 8-LMA-P'07 Arm BAI-haM regimen
02
Targets
DNADNA polymerase familyTOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on cytarabine + idarubicin + mitoxantrone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cytarabine + idarubicin + mitoxantrone.